MBX Biosciences (MBX) Interest Expenses (2023 - 2026)
MBX Biosciences (MBX) posted Interest Expenses of $78.5 million for Q1 2026, up 78411.0% sequentially from $100000.0 in Q4 2025, and up 2386.1% YoY from $3.2 million in Q1 2025.
MBX Biosciences (MBX) Interest Expenses (2023 - 2026) Analysis & Trends
MBX Biosciences has reported Interest Expenses for 4 years, with the latest figure at $78.5 million in Q1 2026.
- Quarterly Interest Expenses rose 2386.1% year-over-year to $78.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.5 million (up 2386.1% YoY) and the FY2025 annual result came in at $97.8 million, up 135.79% from the prior year.
- Interest Expenses climbed to $78.5 million in Q1 2026 per MBX's latest filing, from $100000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $78.5 million in Q1 2026 and troughed at $100000.0 in Q1 2024.
- A 4-year average of $15.3 million and a median of $3.2 million in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses plunged 97.8% in 2024, then surged 12834.0% in 2025.
- Over 4 years, Interest Expenses stood at $4.5 million in 2023, then slumped by 97.8% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then soared by 78411.0% to $78.5 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $78.5 million, $100000.0, and $38.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | MBX Biosciences | 3.29 Bn | 3.29 Bn | - | 186.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 186.70 Mn |
| Jun 30, 2026 | 186.70 Mn |
| Mar 31, 2026 | 78.51 Mn |
| Mar 31, 2026 | 78.51 Mn |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 38.15 Mn |
| Sep 30, 2025 | 38.15 Mn |
| Jun 30, 2025 | 12.93 Mn |
| Jun 30, 2025 | 12.93 Mn |
| Mar 31, 2025 | 3.16 Mn |
| Mar 31, 2025 | 3.16 Mn |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 4.54 Mn |
| Dec 31, 2023 | 4.54 Mn |